enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves 1st new drug for schizophrenia in more ... - AOL

   www.aol.com/fda-approves-1st-drug-schizophrenia...

   Cobenfy offers new hope for people with schizophrenia, providing an innovative treatment option that could change how this condition is managed, according to Jelena Kunovac, MD, a board-certified ...

3. FDA Approves the First New Schizophrenia Drug in Decades - AOL

   www.aol.com/fda-approves-first-schizophrenia...

   Kakar—a psychiatrist who treats patients as well as conducts research—says that historically, only about 40% of people with schizophrenia respond to dopamine-based treatments, and the other 60 ...

4. FDA approves new type of schizophrenia drug - AOL

   www.aol.com/news/fda-approves-type-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

5. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   The effectiveness of xanomeline/trospium chloride for the treatment of schizophrenia in adults was evaluated in two studies with identical designs. [2] Study 1 (NCT04659161) and study 2 (NCT04738123) were 5-week, randomized, double-blind, placebo-controlled, multi-center studies in adults with a diagnosis of schizophrenia according to DSM-5 ...

6. Schizophrenia In America - The Huffington Post

   highline.huffingtonpost.com/articles/en/stop-the...

   More than 40 percent of all people with schizophrenia end up in supervised group housing, nursing homes or hospitals. Another 6 percent end up in jail, usually for misdemeanors or petty crimes, while an equal proportion end up on the streets. Among researchers, schizophrenia has long been known as the “graveyard of psychiatric research.”

7. Roluperidone - Wikipedia

   en.wikipedia.org/wiki/Roluperidone

   Minerva believed that the findings of this second trial supported the claim that the drug was an effective agent for the treatment of negative symptoms in schizophrenia. However, in October 2022, FDA sent Minerva a refusal to file letter pertaining to the New Drug Application for roluperidone for treating negative symptoms in schizophrenia ...